CandlesenseCandlesense
News/Companies/ACHV

ACHV News

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

ACHV

(NASDAQ:ACHV) SEATTLE and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that Rick Stewart, CEO of Achieve Life Sciences, will be participating at two upcoming conferences. Details are as follows:

September 2, 2025Investor
Read more →

Achieve Life Sciences To Present Phase 3 ORCA-3 Study Data At 2025 ATS International Conference

ACHV

May 20, 2025
Read more →

Achieve Life Sciences Says Cytisinicline Phase 3 ORCA-3 Trial Results Showed Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo

ACHV

April 21, 2025
Read more →

Achieve Life Sciences Q4 EPS $(0.36) Misses $(0.32) Estimate

ACHV

March 11, 2025
Read more →

This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

ACHV

November 14, 2024
Read more →

Rodman & Renshaw Initiates Coverage On Achieve Life Sciences with Buy Rating, Announces Price Target of $12

ACHV

November 14, 2024
Read more →

Achieve Life Sciences To Present Cytisinicline ORCA-V1 Program Data At SGIM Annual Meeting

ACHV

May 17, 2024
Read more →

ACHV: Topline Data from ORCA-2 Smoking Cessation Trial

ACHV

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

May 3, 2022
Read more →

Zacks Small-Cap Research Sets New $75 Price Target On Achieve Life Sciences

ACHV

April 28, 2022
Read more →